Kis’ expertise lies in the area of vaccine manufacturing he works to design novel technologies capable of producing large amounts of vaccines against known and unknown pathogens. “Scaling up vaccine production is challenging and the lack of sufficient manufacturing plants is hampering the global vaccine supply,” said Zoltán Kis, a chemical engineer at the Future Vaccine Manufacturing Hub at Imperial College London. At present, very few countries have the domestic capacity to manufacture COVID-19 vaccines. Scientists believe that the large-scale production of COVID-19 vaccines is limited owing to the highly concentrated state of global vaccine manufacturing capacity. This problem was further exacerbated owing to the massive global demand for large-scale production of vaccines currently. Before the ongoing COVID-19 pandemic, there was a lack of established networks of contract manufacturers. Such an incident occurred recently when India and the European Union announced restrictions on vaccine exports. According to Duke University’s Andrea Taylor, leader of global innovation programs on evaluation, scaling and adaptation of healthcare innovations to address critical access and quality challenges, a break in the supply chain can occur owing to various reasons, such as the exporting countries threatening to block vaccine component shipments. In a summit of manufacturers and policymakers, Richard Hatchett, chief executive of the Coalition for Epidemic Preparedness Innovations, pointed out that if the supply of one of the components falls short, the production of the vaccine can be delayed. These components, such as glass vials, syringes, filters, tubing, stabilizing agents and disposable bags, are often produced in different countries. Typically, more than 200 individual components are required for the production of a vaccine. The transition from manufacturing vaccines in smaller quantities required for academic research to the mass production that is required to protect the global population can be a daunting task.Ĭhallenges in the large-scale production of vaccines To vaccinate the global population, the world needs billions of vaccine doses, quickly. Although pharmaceutical companies have been able to manufacture hundreds of millions of doses of COVID-19 vaccines in a short period, demand continues to increase. In the current situation, an added challenge is achieving large-scale production at a rapid pace. Thereby, many researchers are working at record speed to develop COVID-19 vaccines, and to date, many new vaccines have received emergency use authorization (EUA) from global regulatory bodies, such as the US Food and Drug Administration (FDA), the Medicines and Healthcare products Regulatory Agency (MHRA) and the European Medicines Agency (EMA).Īfter a new vaccine is designed, the main challenge that the manufacturers face is scaling up its production. Limited success in designing new drugs and repurposing existing drugs to treat COVID-19, has led to a research focus on preventives, which includes vaccines. It has also had a humongous impact on the global economy. That helps you maintain the integrity and activity of vaccine products.The ongoing COVID-19 pandemic is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and has claimed over 3.1 million lives worldwide. We combine our product knowledge with our in-depth understanding of how chemicals perform in cell culture systems from discovery through product development, pre-clinical, scale-up, and commercial vaccine manufacturing. We can help you improve your development and manufacturing processes by providing high-quality, ready-to-use, pre-weighed, and pre-packaged cGMP chemicals, including: Process Development Expertise and Solutions for Every Stage of Vaccine Manufacturing WorkflowsĪvantor supplies a wide range of cGMP chemicals and excipients, sera, single-use solutions, and other raw materials for vaccine development and manufacturing, including solutions that support COVID-19 vaccines.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |